Skip to main content
SpringerLink
Log in

Class B GPCR: Receptors and RAMPs

  • Chapter
  • First Online:
G-Protein-Coupled Receptor Dimers

Part of the book series: The Receptors ((REC,volume 33))

  • 1308 Accesses

Abstract

Receptor activity-modifying proteins (RAMPs) are a family of three single transmembrane spanning proteins. They were first identified based on their ability to facilitate the cell surface expression of a G protein-coupled receptor (GPCR), named the calcitonin receptor-like receptor (CLR). They also determine whether CLR can be activated by calcitonin-gene related peptide (CGRP) or adrenomedullin (AM). We now know that RAMPs can interact with a number of GPCRs, including the calcitonin receptor. The interaction between a GPCR and RAMP can influence cell surface expression and trafficking, determine hormone specificity and regulate intracellular signaling and/or G protein-coupling in a receptor-specific manner. This chapter will review recent advances in the RAMP field, paying particular attention to receptors formed by the co-expression of CLR and RAMPs. We will detail the known GPCR partners for RAMPs and describe how these interactions with RAMP can influence GPCR function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science. 1991;254(5034):1022–4.

    Article  CAS  PubMed  Google Scholar 

  2. Njuki F, Nicholl CG, Howard A, Mak JC, Barnes PJ, Girgis SI, et al. A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin Sci (Lond). 1993;85(4):385–8.

    Article  CAS  Google Scholar 

  3. Fluhmann B, Muff R, Hunziker W, Fischer JA, Born W. A human orphan calcitonin receptor-like structure. Biochem Biophys Res Commun. 1995;206(1):341–7.

    Article  CAS  PubMed  Google Scholar 

  4. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54(2):233–46.

    Article  CAS  PubMed  Google Scholar 

  5. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393(6683):333–9.

    Article  CAS  PubMed  Google Scholar 

  6. Muff R, Buhlmann N, Fischer JA, Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or −3. Endocrinology. 1999;140(6):2924–7.

    Article  CAS  PubMed  Google Scholar 

  7. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56(1):235–42.

    CAS  PubMed  Google Scholar 

  8. Armour SL, Foord S, Kenakin T, Chen WJ. Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol Methods. 1999;42(4):217–24.

    Article  CAS  PubMed  Google Scholar 

  9. Oliver KR, Kane SA, Salvatore CA, Mallee JJ, Kinsey AM, Koblan KS, et al. Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. Eur J Neurosci. 2001;14(4):618–28.

    Article  CAS  PubMed  Google Scholar 

  10. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther. 2006;109(1–2):173–97.

    Article  CAS  PubMed  Google Scholar 

  11. Archbold JK, Flanagan JU, Watkins HA, Gingell JJ, Hay DL. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci. 2011;32(10):591–600.

    Article  CAS  PubMed  Google Scholar 

  12. Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, Foord SM. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol. 1999;55(6):1054–9.

    CAS  PubMed  Google Scholar 

  13. Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord SM, Sexton PM. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem Biophys Res Commun. 2000;267(1):368–72.

    Article  CAS  PubMed  Google Scholar 

  14. Fitzsimmons TJ, Zhao X, Wank SA. The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function. J Biol Chem. 2003;278(16):14313–20.

    Article  CAS  PubMed  Google Scholar 

  15. Moad HE, Pioszak AA. Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins. Protein Sci Publ Protein Soc. 2013;22(12):1775–85.

    Article  CAS  Google Scholar 

  16. Booe JM, Walker CS, Barwell J, Kuteyi G, Simms J, Jamaluddin MA, et al. Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Mol Cell. 2015;58(6):1040–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kusano S, Kukimoto-Niino M, Akasaka R, Toyama M, Terada T, Shirouzu M, et al. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci Publ Protein Soc. 2008;17(11):1907–14.

    Article  CAS  Google Scholar 

  18. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure. 2010;18(9):1083–93.

    Article  PubMed  Google Scholar 

  19. Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K, et al. Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding. Protein Sci Publ Protein Soc. 2012;21(2):199–210.

    Article  CAS  Google Scholar 

  20. Rist B, Lacroix JS, Entzeroth M, Doods HN, Beck-Sickinger AG. CGRP 27–37 analogues with high affinity to the CGRP1 receptor show antagonistic properties in a rat blood flow assay. Regul Pept. 1999;79(2–3):153–8.

    Article  CAS  PubMed  Google Scholar 

  21. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci. 2009;34(6):303–10.

    Article  CAS  PubMed  Google Scholar 

  22. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-d ibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny l) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1. Mol Pharmacol. 2006;70(6):1984–91.

    Article  CAS  PubMed  Google Scholar 

  23. Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL. Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol. 2008;74(4):1059–71.

    Article  CAS  PubMed  Google Scholar 

  24. Johansson E, Hansen JL, Hansen AM, Shaw AC, Becker P, Schaffer L, et al. Type II turn of receptor-bound Salmon Calcitonin revealed by X-ray crystallography. J Biol Chem. 2016;291(26):13689–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lee SM, Hay DL, Pioszak AA. Calcitonin and amylin receptor peptide interaction mechanisms: insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins. J Biol Chem. 2016;291(16):8686–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gingell JJ, Simms J, Barwell J, Poyner DR, Watkins HA, Pioszak AA, et al. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discovery. 2016;2:16012.

    Article  CAS  Google Scholar 

  27. Gingell JJ, Qi T, Bailey RJ, Hay DL. A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor. Peptides. 2010;31(7):1400–4.

    Article  CAS  PubMed  Google Scholar 

  28. Moore EL, Gingell JJ, Kane SA, Hay DL, Salvatore CA. Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. Biochem Biophys Res Commun. 2010;394(1):141–5.

    Article  CAS  PubMed  Google Scholar 

  29. Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Insights into the structure of class B GPCRs. Trends Pharmacol Sci. 2014;35(1):12–22.

    Article  CAS  PubMed  Google Scholar 

  30. Watkins HA, Chakravarthy M, Abhayawardana RS, Gingell JJ, Garelja M, Pardamwar M, et al. Receptor activity-modifying proteins 2 and 3 generate adrenomedullin receptor subtypes with distinct molecular properties. J Biol Chem. 2016;291(22):11657–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Udawela M, Christopoulos G, Morfis M, Christopoulos A, Ye S, Tilakaratne N, et al. A critical role for the short intracellular C terminus in receptor activity-modifying protein function. Mol Pharmacol. 2006;70(5):1750–60.

    Article  CAS  PubMed  Google Scholar 

  32. Udawela M, Christopoulos G, Morfis M, Tilakaratne N, Christopoulos A, Sexton PM. The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors. Regul Pept. 2008;145(1–3):65–71.

    Google Scholar 

  33. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ. Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry. 2009;48(49):11773–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Steiner S, Muff R, Gujer R, Fischer JA, Born W. The transmembrane domain of receptor-activity-modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. Biochemistry. 2002;41(38):11398–404.

    Article  CAS  PubMed  Google Scholar 

  35. Wootten D, Lindmark H, Kadmiel M, Willcockson H, Caron KM, Barwell J, et al. Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function. Br J Pharmacol. 2013;168(4):822–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bouschet T, Martin S, Henley JM. Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci. 2005;118(Pt 20):4709–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lenhart PM, Nguyen T, Wise A, Caron KM, Herring AH, Stuebe AM. Adrenomedullin signaling pathway polymorphisms and adverse pregnancy outcomes. Am J Perinatol. 2014;31(4):327–34.

    Article  PubMed  Google Scholar 

  38. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem. 2003;278(5):3293–7.

    Article  CAS  PubMed  Google Scholar 

  39. Weston C, Lu J, Li N, Barkan K, Richards GO, Roberts DJ, et al. Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2). J Biol Chem. 2015;290(38):23009–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kuwasako K, Shimekake Y, Masuda M, Nakahara K, Yoshida T, Kitaura M, et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem. 2000;275(38):29602–9.

    Article  CAS  PubMed  Google Scholar 

  41. Hilairet S, Belanger C, Bertrand J, Laperriere A, Foord SM, Bouvier M. Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol Chem. 2001;276(45):42182–90.

    Article  CAS  PubMed  Google Scholar 

  42. Bomberger JM, Spielman WS, Hall CS, Weinman EJ, Parameswaran N. Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. J Biol Chem. 2005;280(25):23926–35.

    Article  CAS  PubMed  Google Scholar 

  43. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem. 2005;280(10):9297–307.

    Article  CAS  PubMed  Google Scholar 

  44. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature. 2011;477(7366):549–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kang Y, Zhou XE, Gao X, He Y, Liu W, Ishchenko A, et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature. 2015;523(7562):561–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Walker CS, Conner AC, Poyner DR, Hay DL. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci. 2010;31(10):476–83.

    Article  CAS  PubMed  Google Scholar 

  47. Kuwasako K, Kitamura K, Nagata S, Hikosaka T, Kato J. Function of the cytoplasmic tail of human calcitonin receptor-like receptor in complex with receptor activity-modifying protein 2. Biochem Biophys Res Commun. 2010;392(3):380–5.

    Article  CAS  PubMed  Google Scholar 

  48. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012;52:179–97.

    Article  CAS  PubMed  Google Scholar 

  49. Hay DL, Harris PW, Kowalczyk R, Brimble MA, Rathbone DL, Barwell J, et al. Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation. Br J Pharmacol. 2014;171(2):415–26.

    Article  CAS  PubMed  Google Scholar 

  50. Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL, et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol. 1994;46(2):246–55.

    CAS  PubMed  Google Scholar 

  51. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol. 2005;67(5):1655–65.

    Article  CAS  PubMed  Google Scholar 

  52. Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A, et al. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology. 2008;149(11):5423–31.

    Article  CAS  PubMed  Google Scholar 

  53. Qi T, Dong M, Watkins HA, Wootten D, Miller LJ, Hay DL. Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Delta(1–47)hCT((a)) function. Br J Pharmacol. 2013;168(3):644–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Muller JM, Debaigt C, Goursaud S, Montoni A, Pineau N, Meunier AC, et al. Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update. Peptides. 2007;28(9):1655–66.

    Article  CAS  PubMed  Google Scholar 

  55. Hay DL, Pioszak AA. Receptor activity-modifying proteins (RAMPs): new insights and roles. Annu Rev Pharmacol Toxicol. 2016;56:469–87.

    Article  CAS  PubMed  Google Scholar 

  56. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–96.

    Article  CAS  PubMed  Google Scholar 

  57. Eftekhari S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci. 2011;12:112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2(6):595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Tsujikawa K, Yayama K, Hayashi T, Matsushita H, Yamaguchi T, Shigeno T, et al. Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc Natl Acad Sci U S A. 2007;104(42):16702–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Li M, Wetzel-Strong SE, Hua X, Tilley SL, Oswald E, Krummel MF, et al. Deficiency of RAMP1 attenuates antigen-induced airway hyperresponsiveness in mice. PLoS One. 2014;9(7):e102356.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Zhang Z, Dickerson IM, Russo AF. Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology. 2006;147(4):1932–40.

    Article  CAS  PubMed  Google Scholar 

  62. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27(10):2693–03.

    Article  CAS  PubMed  Google Scholar 

  63. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564–600.

    Article  CAS  PubMed  Google Scholar 

  64. Zhang Z, Liu X, Morgan DA, Kuburas A, Thedens DR, Russo AF, et al. Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice. Diabetes. 2011;60(4):1063–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Fernandes-Santos C, Zhang Z, Morgan DA, Guo DF, Russo AF, Rahmouni K. Amylin acts in the central nervous system to increase sympathetic nerve activity. Endocrinology. 2013;154(7):2481–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Dackor R, Fritz-Six K, Smithies O, Caron K. Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem. 2007;282(25):18094–9.

    Article  CAS  PubMed  Google Scholar 

  67. Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest. 2008;118(1):40–50.

    Article  CAS  PubMed  Google Scholar 

  68. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T, et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest. 2008;118(1):29–39.

    Article  CAS  PubMed  Google Scholar 

  69. Kadmiel M, Fritz-Six K, Pacharne S, Richards GO, Li M, Skerry TM, et al. Research resource: haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in mice. Mol Endocrinol. 2011;25(7):1244–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The School of Biological Sciences, The University of Auckland, 3A Symonds Street, Auckland, 1142, New Zealand

    Joseph J. Gingell Ph.D., Christopher S. Walker Ph.D. & Debbie L. Hay B.Sc., Ph.D.

Authors
  1. Joseph J. Gingell Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher S. Walker Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Debbie L. Hay B.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Debbie L. Hay B.Sc., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York, USA

    Katharine Herrick-Davis

  2. Centre for Translational Pharmacology, Institute of Molecular Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

    Graeme Milligan

  3. Department of Physiology and Biochemistry, University of Malta, Msida, Malta

    Giuseppe Di Giovanni

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Gingell, J.J., Walker, C.S., Hay, D.L. (2017). Class B GPCR: Receptors and RAMPs. In: Herrick-Davis, K., Milligan, G., Di Giovanni, G. (eds) G-Protein-Coupled Receptor Dimers. The Receptors, vol 33. Humana Press, Cham. https://doi.org/10.1007/978-3-319-60174-8_11

Download citation

Publish with us

Policies and ethics

Search

Navigation